Supriya Lifescience Corporate Filings & Announcements

Latest corporate announcements and filings from Supriya Lifescience on BSE

Search Inside the pdf :

Supriya Lifescience Ltd.

30 Dec 2025

744.75

-0.77%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation on Credit Rating to the Company is enclosed.

pdf

Supriya Lifescience Ltd.

28 Dec 2025

744.75

-0.77%

SAST

Supriya Lifescience Ltd - 543434 - Closure of Trading Window

BSE India

Intimation for Closure of Trading Window for declaration of the Unaudited Financial Results for quarter and nine months ending on December 31, 2025. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

26 Nov 2025

744.75

-0.77%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on Tuesday, December 2, 2025 as per details attached herewith. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

18 Nov 2025

744.75

-0.77%

Earnings Call

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2025, is enclosed herewith. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

13 Nov 2025

744.75

-0.77%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication for the Unaudited Financial Results for the Quarter and Half year ended September 30, 2025 is enclosed herewith.

pdf

Supriya Lifescience Ltd.

13 Nov 2025

744.75

-0.77%

Company Update

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release for the Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025 is enclosed herewith.

pdf

Supriya Lifescience Ltd.

12 Nov 2025

744.75

-0.77%

Investor Presentation

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Investor Presentation is enclosed herewith.

pdf

Supriya Lifescience Ltd.

12 Nov 2025

744.75

-0.77%

Result

Supriya Lifescience Ltd - 543434 - Unaudited Financial Results For The Quarter And Half Year Ended …

BSE India

Unaudited Financial Results for the Quarter and Half year ended September 30,2025 are enclosed herewith. Kindly take the same on record.

pdf

Supriya Lifescience Ltd.

12 Nov 2025

744.75

-0.77%

Board Meeting

Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, November 12, 2025, inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015. The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 03.30 p.m. Kindly take the above information on your records.

pdf

Supriya Lifescience Ltd.

09 Nov 2025

744.75

-0.77%

Investor Presentation

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Thursday, November 13, 2025 at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and half year ended September 30, 2025. The invite giving requisite details including the pre-registration link and dial-in details is enclosed herewith. The investor presentation shall be shared with the Exchanges separately. Kindly take the information on record.

pdf

VOTE: Is Supriya Lifescience Ltd. worth buying?

115 Votes:

Buy 86.96%

Sell 6.09%

Hold 6.96%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf